Gadofosveset

Gadofosveset Uses, Dosage, Side Effects, Food Interaction and all others data.

Gadofosveset is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.

Gadofosveset causes signal enhancement by shortening the T1 of water molecules that interact with it. The contrast agent complex's rotation rate is the primary factor determining the magnitude of relaxation enhancement. This relaxation enhancement increase only occurs when bound to human serum albumin.

Gadofosveset
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Gadofosveset
Generic	Gadofosveset trisodium
Gadofosveset trisodium Other Names	Gadofosveset
Type	Injection
Formula	C₃₃H₃₈GdN₃Na₃O₁₄P
Weight	Average: 957.87 Monoisotopic: 958.10256
Protein binding	80-90%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Gadofosveset is an intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease.

Gadofosveset is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

Gadofosveset is also used to associated treatment for these conditions: Aortoiliac Occlusive Disease

How Gadofosveset works

Gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (Tl) of water protons resulting in an increase in signal intensity (brightness) of blood.

Toxicity

Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m²).

Food Interaction

No interactions found.

Volume of Distribution

48 ± 16 mL/kg

Half Life

18.5 hours

Clearance

6.57 ± 0.97 mL/h/kg following the administration of 0.03 mmol/kg.

Elimination Route

Gadofosveset is eliminated primarily in the urine with approximately 83.5% of an injected dose excreted in the urine over 14 days. Ninety-four percent (94%) of urinary excretion occurs in the first 72 hours. A small portion of gadofosveset dose is recovered in feces (approximately 4.7%).